Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedNov 03, 2025
DataAggregated Company Financials
Companies5
  • 7D1.0%
  • 3M29.5%
  • 1Y-2.4%
  • YTD4.1%

In the last week, the Biotech industry is up 1.0%, with Zealand Pharma up 12%. Overall in the last year, the industry is flat. In the next few years, earnings are forecast to decline by 11% annually.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 04 Nov 2025DKK 168.5bDKK 39.2bDKK 16.9b12.7x10x4.3x
Thu, 02 Oct 2025DKK 175.7bDKK 38.8bDKK 16.7b12.6x10.5x4.5x
Sat, 30 Aug 2025DKK 147.5bDKK 38.9bDKK 16.8b11.2x8.8x3.8x
Mon, 28 Jul 2025DKK 137.1bDKK 26.9bDKK 7.3b13.2x18.8x5.1x
Wed, 25 Jun 2025DKK 121.9bDKK 27.1bDKK 7.4b10.6x16.5x4.5x
Fri, 23 May 2025DKK 128.7bDKK 28.0bDKK 7.9b10.5x16.3x4.6x
Sun, 20 Apr 2025DKK 124.4bDKK 27.3bDKK 7.7b11.2x16.2x4.6x
Tue, 18 Mar 2025DKK 143.4bDKK 27.3bDKK 7.7b12.2x18.7x5.2x
Thu, 13 Feb 2025DKK 151.2bDKK 26.0bDKK 4.7b15.2x32.2x5.8x
Sat, 11 Jan 2025DKK 170.6bDKK 26.0bDKK 4.7b17.9x36.3x6.6x
Mon, 09 Dec 2024DKK 173.1bDKK 26.0bDKK 4.7b17.8x36.9x6.6x
Wed, 06 Nov 2024DKK 172.1bDKK 25.5bDKK 5.5b20.2x31.4x6.8x
Fri, 04 Oct 2024DKK 175.3bDKK 25.5bDKK 5.5b21.6x32x6.9x
Sun, 01 Sep 2024DKK 203.5bDKK 25.5bDKK 5.5b25.4x37.2x8x
Tue, 30 Jul 2024DKK 201.3bDKK 24.8bDKK 5.6b18.6x35.7x8.1x
Thu, 27 Jun 2024DKK 183.5bDKK 24.8bDKK 5.6b17.6x32.6x7.4x
Sat, 25 May 2024DKK 175.6bDKK 24.8bDKK 5.6b18.5x31.2x7.1x
Mon, 22 Apr 2024DKK 178.7bDKK 23.9bDKK 5.0b18.9x35.5x7.5x
Wed, 20 Mar 2024DKK 189.8bDKK 23.9bDKK 5.0b19.3x37.8x7.9x
Fri, 16 Feb 2024DKK 172.9bDKK 22.8bDKK 4.2b23.5x41x7.6x
Sun, 14 Jan 2024DKK 182.0bDKK 23.3bDKK 4.2b25.5x43.7x7.8x
Tue, 12 Dec 2023DKK 178.5bDKK 23.3bDKK 4.2b26x42.9x7.7x
Thu, 09 Nov 2023DKK 170.8bDKK 22.7bDKK 4.3b21.7x39.8x7.5x
Sat, 07 Oct 2023DKK 193.2bDKK 22.0bDKK 4.7b22.7x40.8x8.8x
Mon, 04 Sep 2023DKK 200.9bDKK 22.0bDKK 4.7b23.8x42.5x9.1x
Wed, 02 Aug 2023DKK 203.7bDKK 19.5bDKK 4.4b35.2x46.2x10.4x
Fri, 30 Jun 2023DKK 195.0bDKK 19.5bDKK 4.4b40.9x44.3x10x
Sun, 28 May 2023DKK 214.9bDKK 19.5bDKK 4.4b42.1x48.8x11x
Tue, 25 Apr 2023DKK 211.6bDKK 17.9bDKK 3.5b33.1x59.8x11.8x
Thu, 23 Mar 2023DKK 191.2bDKK 17.9bDKK 3.5b29.9x53.9x10.7x
Sat, 18 Feb 2023DKK 208.8bDKK 14.7bDKK 3.3b31.9x63.8x14.2x
Mon, 16 Jan 2023DKK 208.7bDKK 14.7bDKK 3.3b32x63.8x14.2x
Wed, 14 Dec 2022DKK 235.3bDKK 14.7bDKK 3.3b36.9x71.9x16x
Fri, 11 Nov 2022DKK 232.4bDKK 14.7bDKK 3.3b36x70.3x15.8x
Price to Earnings Ratio

70.3x


Total Market Cap: DKK 232.4bTotal Earnings: DKK 3.3bTotal Revenue: DKK 14.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 37.4x202320242025
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 10.0x which is lower than its 3-year average PE of 37.4x.
  • The 3-year average PS ratio of 8.1x is higher than the industry's current PS ratio of 4.3x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 72% per year over the last three years.
  • Revenues for these companies have grown 39% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market-3.04%
Healthcare-5.96%
Biotech1.01%
Biotech1.01%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ZEAL Zealand PharmaDKK 485.205.6%
+DKK 1.8b		-42.6%PE5.1x
STRAP Strategic PartnersDKK 890.004.5%
+DKK 1.6m		-13.9%PB2.1x

Latest News

GMAB
DKK 1,864.50
Genmab
7D
-0.3%
1Y
20.1%

GMAB: Recent Acquisition Will Drive Pipeline Expansion While Integration Risks Remain

Genmab's fair value estimate has been raised from DKK 2,012.92 to DKK 2,017.35. Analysts highlight the Merus acquisition's positive impact on the late-stage pipeline and renewed confidence in royalty revenue growth opportunities.
BAVA
DKK 235.00
Bavarian Nordic
7D
-2.1%
1Y
9.8%

Local Spread Of New Mpox Strain Will Challenge Future Vaccine Margins

Narrative Update on Bavarian Nordic Analysts have raised their fair value price target for Bavarian Nordic from €244 to €250, citing modest improvements in valuation assumptions and financial projections. What's in the News Officials in California have confirmed community spread of the new clade 1 Mpox strain among residents with no recent international travel.
ZEAL
DKK 485.20
Zealand Pharma
7D
5.6%
1Y
-42.6%
STRAP
DKK 890.00
Strategic Partners
7D
4.5%
1Y
-13.9%
BIOPOR
DKK 1.29
BioPorto
7D
-0.2%
1Y
-31.9%